Health insurance company Clover Health (NASDAQ:CLOV) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 33.3% year on year to $462.3 million. Its non-GAAP profit of $0.05 per share was significantly above analysts’ consensus estimates.
Home and security products company Fortune Brands (NYSE:FBIN) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 6.9% year on year to $1.03 billion. Its non-GAAP profit of $0.66 per share was in line with analysts’ consensus estimates.
Medical tech company Masimo (NASDAQ:MASI) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.5% year on year to $372 million. The company expects the full year’s revenue to be around $1.52 billion, close to analysts’ estimates. Its non-GAAP profit of $1.36 per share was 12.6% above analysts’ consensus estimates.
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 80.2% year on year to $744.9 million. Its non-GAAP loss of $3.42 per share was significantly below analysts’ consensus estimates.
Senior living provider The Pennant Group (NASDAQ:PNTG) announced better-than-expected revenue in Q1 CY2025, with sales up 33.7% year on year to $209.8 million. Its non-GAAP profit of $0.27 per share was 13.7% above analysts’ consensus estimates.
Higher education company Grand Canyon Education (NASDAQ:LOPE) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 5.3% year on year to $289.3 million. The company expects next quarter’s revenue to be around $240.3 million, close to analysts’ estimates. Its GAAP profit of $2.52 per share was 2.9% above analysts’ consensus estimates.
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the midpoint came in 3.7% below analysts’ estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts’ consensus estimates.
Cross border payment processor Flywire (NASDAQ: FLYW) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 17% year on year to $133.5 million. The company expects next quarter’s revenue to be around $124.4 million, close to analysts’ estimates. Its non-GAAP profit of $0.11 per share was in line with analysts’ consensus estimates.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $4.28 billion at the midpoint. Its non-GAAP profit of $1.68 per share was 63.9% below analysts’ consensus estimates.
Wellness products company Nature’s Sunshine (NASDAQ:NATR) announced better-than-expected revenue in Q1 CY2025, with sales up 2% year on year to $113.2 million. The company expects the full year’s revenue to be around $457.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.25 per share was 51.5% above analysts’ consensus estimates.
Technology real estate company Opendoor (NASDAQ:OPEN) announced better-than-expected revenue in Q1 CY2025, but sales fell by 2.4% year on year to $1.15 billion. On the other hand, next quarter’s revenue guidance of $1.49 billion was less impressive, coming in 0.8% below analysts’ estimates. Its non-GAAP loss of $0.09 per share was 15.9% above analysts’ consensus estimates.
Data protection and security software company Varonis (NASDAQ:VRNS) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 19.6% year on year to $136.4 million. The company expects next quarter’s revenue to be around $147.5 million, close to analysts’ estimates. Its non-GAAP profit of $0 per share was significantly above analysts’ consensus estimates.
Home automation and security solutions provider Resideo Technologies (NYSE:REZI) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 19.1% year on year to $1.77 billion. The company expects next quarter’s revenue to be around $1.83 billion, close to analysts’ estimates. Its non-GAAP profit of $0.63 per share was significantly above analysts’ consensus estimates.
Residential swimming pool manufacturer Latham (NASDAQ:SWIM) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $111.4 million. The company’s full-year revenue guidance of $550 million at the midpoint came in 2.5% above analysts’ estimates. Its non-GAAP loss of $0.04 per share was in line with analysts’ consensus estimates.
Outdoor living products manufacturer AZEK Company (NYSE:AZEK) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.1% year on year to $452.2 million. On the other hand, the company’s full-year revenue guidance of $1.54 billion at the midpoint came in 0.9% below analysts’ estimates. Its non-GAAP profit of $0.45 per share was 3.1% above analysts’ consensus estimates.
Crane and lifting equipment company Manitowoc (NYSE:MTW) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 4.9% year on year to $470.9 million. Its non-GAAP loss of $0.16 per share was 72.7% below analysts’ consensus estimates.
Data and analytics software provider Teradata (NYSE:TDC) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 10.1% year on year to $418 million. Next quarter’s revenue guidance of $401.1 million underwhelmed, coming in 1.4% below analysts’ estimates. Its non-GAAP profit of $0.66 per share was 16.9% above analysts’ consensus estimates.
